Biological feasibility of developing prophylactic vaccines for viral pathogens: Incubation period as a critical parameter

Human Vaccines

Volumn 3, Issue 1, 2007, Pages 1-7

  Kaslow, David C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Incubation period; Risk; Uncertainty; Vaccine development; Viral pathogens

Indexed keywords

ADENOVIRUS VACCINE; CYTOMEGALOVIRUS VACCINE; DENGUE VACCINE; EPSTEIN BARR VIRUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HERPES SIMPLEX VACCINE; HUMAN HERPESVIRUS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; MEASLES VACCINE; METAPNEUMOVIRUS VACCINE; MUMPS VACCINE; PARAINFLUENZA VACCINE; POLIOMYELITIS VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RHINOVIRUS VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; SMALLPOX VACCINE; TICK BORNE ENCEPHALITIS VACCINE; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; VIRUS VACCINE; WART VIRUS VACCINE; WEST NILE VACCINE; YELLOW FEVER VACCINE;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; DRUG EFFICACY; GENE STRUCTURE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INCUBATION TIME; INNATE IMMUNITY; NONHUMAN; REVIEW; SYSTEMATIC REVIEW; T LYMPHOCYTE; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 33847074224     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.3.1.3519     Document Type: Review

References (118)

1. Stewart JJ, Allison PN, Johnson RS. Putting a price on biotechnology. Nature Biotech 2001; 19:813-7.
2. Kaslow D. A potential disruptive technology in vaccine development: Gene-based vaccines and their application to infectious diseases. Trans R Soc Trop Med Hyg 2004; 98:593-601.
3. Harris JM, Gwaltney JM. Incubation periods of experimental rhinovirus infection and illness. Clin Infect Dis 1996; 23:1287-90.
4. Savolainen C, Blomqvist S, Muiders MN, Hovi T. Genetic clustering of all 102 human rhinovirus prototype strains: Serotype 87 is close to human enterovirus 70. J Gen Vitol 2002; 83:333-40.
5. Gwaltney Jr JM, Hendley JO, Simon G, Jordan Jr WS. Rhinovirus infections in an industrial population. II. Characteristics of illness and antibody response. JAMA 1967; 202:494-500.
6. Fox JP, Cooney MK, Hall CE, Foy HM. Rhinoviruses in Seattle families, 1975-1979. Am J Epidemiol 1985; 122:830-46.
7. Moser MR, Bender TR, Margolis HS, Noble GR, Kendal AP, Ritter DG. An outbreak of influenza aboard a commercial airliner. Am J Epidemiol 1979; 110:1-6.
8. Hirst GK, Gotlieb T. The experimental production of combination forms of virus. II. A study of serial passage in the allantoic sac of agents that combine the antigens of two distinct influenza A strains. J Exp Med 1953; 98:53-70.
9. Hilleman MR. Realities and enigmas of human viral influenza: Pathogenesis, epidemiology and control. Vaccine 2002; 20:3068-87.
10. Tyrrell DAJ, Bynoe ML, Birkum Petersen K Sutton RNP, Pereira MS. Inoculation of human volunteers with parainfluenza viruses types 1 and 3 (HA2 and HA1). Br Med J 1959; 2:909-11.
11. Chanock RM, Vargosko A, Luckey A, Cook MK, Kapikian AZ, Reicelderfer T, Parrott RH. Association of hemadsorption viruses with respiratory illness in childhood. J Am Med Assoc 1959; 169:548-53.
12. Chanock RM, Parrott RH, Johnson KM, Kapikian AZ, Bell JA. Myxoviruses: Parainfluenza. Am Rev Respir Dis 1963; 88:152-66.
13. Bloom HH, Johnson KM, Jacobsen R, Chanock RM. Recovery of parainfluenza viruses from adults with upper respiratory illness. Am J Hyg 1961; 74:50-9.
14. Glezen WP, Frank AL, Taber LH, Kasel JA. Parainfluenza virus type 3:seasonality and risk of infection and reinfection in young children. J Infect Dis 1984; 150:851-7.
15. Coelingh KV, Winter CC. Naturally occurring human parainfluenza type 3 viruses exhibit divergence in amino acid sequence of their fusion protein neutralization epitopes and cleavage sites. J Virol 1990; 64:1329-34.
16. van Wyke Coelingh KL, Winter CC, Tierney EL, Hall SL, London WT, Kim HW, Chanock RM, Murphy BR. Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins aftet primary infection or reinfection with parainfluenza type 3 virus. J Virol 1990; 64:3833-43.
17. Ward RL, Bernstein DI, Shukla R, Young EC, Sherwood JR, McNeal MM, Walker MC, Schiff GM. Effects of antibody to rotaviruson protection of adults challenged with a human rotavirus. J Infect Dis 1989; 159:79-88.
18. Grimwood K, Abbott GD, Fergusson DM, Jennings LC, Allan JM. Spread of rotavirus within families:a community based study. Br Med J 1983; 287:575-7.
19. Kapikian AZ, Wyatt RG, Levine MM, Yolken RH, VanKirk DH, Dolin R, Greenberg HB, Chanock RM. Oral administration of human rotavirus to volunteers: Induction of illness and correlates of resistance. J Infect Dis 1983; 147:95-106.
20. Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K, Ramachandran M, Jain V, Cunliffe NA Nakagomi O, Kirkwood CD, Fischer TK, Parashar UD, Bresee JS, Jiang B, Glass RI. Serotype diversity and reassortment between human and animal rotavirus strains: Implications for totavirus vaccine programs. J Infect Dis 2005; 92:S146-59.
21. Coulson BS, Grimwood K, Hudson IL, Barnes GL, Bishop RF. Role of coproantibody in clinical protection of children during reinfection with rotavirus. J Clin Microbiol 1992; 30:1678-84.
22. Kapikian AZ, Bell JA, Mastroda F, Johnson KM, Huebner RJ, Chanock RM. An outbreak of febrile illness and pneumonia associated with respiratory syncytial virus infection. Am J Hyg 1961; 74:235-48.
23. Henderson FW, Collier AM, Clyde Jr WA, Denny FW. Respiratory-syncytial- virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979; 300:530-4.
24. Sullender WM. Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev 2000; 13:1-15.
25. Petet TC, Hall CB, Schnabel KC, Golub JA Anderson LJ. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol 1998; 79:2221-9.
26. Meltzer MI. Multiple contact dates and SARS incubation periods. Emerg Infect Dis 2004; 10:207-9.
27. Farewell VT, Herzbetg AM, James KW, Ho LM, Leung GM. SARS incubation and quarantine times: When is an exposed individual known to be disease free? Stat Med 2005; 24:3431-45.
28. Chinese SARS molecular epidemiology consortium. Molecular evolution of the SARS cotonavirus during the course of the SARS epidemic in China. Science 2004; 303:1666-9.
29. Nie Y, Wang G, Shi X, Zhang H, Qiu Y, He Z, Wang W, Lian G, Yin X, Du L, Ren L, Wang J, He X, Li T, Deng H, Ding M. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis 2004; 190:1119-26.
30. Siler JF, Hall MW, Hitchens AP. Dengue: Its history, epidemiology, mechanism of transmission, etiology, clinical manifestations, immunity, and prevention. Philippine J Sci 1926; 29:1-305.
31. Lanciotti RS, Gubler DJ, Trent DW. Molecular evolution and phytogeny of dengue-4 viruses. J Gen Virol 1997; 78:2279-84.
32. Peiris JS, Tang WH, Chan KH, Khong PL, Guan Y, Lau YL, Chiu SS. Children with respiratory disease associated with metapneumovirus in Hong Kong. Emerg Infect Dis 2003; 9:628-33.
33. Pelletier G, Dery P, Abed Y, Boivin G. Respiratory tract reinfections by the new human Metapneumovirus in an immunocompromised child. Emerg Infect Dis 2002; 8:976-8.
34. van den Hoogen BG, Herfst S, Sprang L, Cane PA, Forleo-Neto E, de Swart RL, Osterhaus AD, Fouchier RA. Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis 2004; 10:658-66.
35. Ludewick HP, Abed Y, van Niekerk N, Boivin G, Klugman KP, Madhi SA. Human metapneumovirus genetic variability, South Africa. Emerg Infect Dis 2005; 11:1074-8.
36. Goldblum N, Sterk VM, Paderski B. The clinical features of the disease and the isolation of West Nile virus from the blood of nine human cases. Am J Hygiene 1954; 59:89-103.
37. Lanciotti RS, Ebel GD, Deubel V, Kerst AJ, Murri S, Meyer R, Bowen M, McKinney N, Morrill WE, Crabtree MB, Kramer LD, Roehrig JT. Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East. Virology 2002; 298:96-105.
38. Thin RN. Does first episode genital herpes have an incubation period? A clinical study. Interntl J of STD and AIDS 1991; 2:285-6.
39. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: Clinical manifestations, course, and complications. Ann Intern Med 1983; 98:958-72.
40. Manzella JP, McConville JH, Valenti W Menegus MA, Swierkosz EM, Arens M. An outbreak of herpes simplex virus type I gingivostomatitis in a dental hygiene practice. JAMA 1984; 252:2019-22.
41. Richmond SJ, Caul EO, Dunn SM, Ashley CR, Clarke SK, Seymour NR. An outbreak of gastroenteritis in young children caused by adenoviruses. Lancet 1979; 1:1178-81.
42. De Jong JC, Wermenbol AG, Verweij-Uijterwaal MW Slaterus KW, Wertheim-Van Dillen P, Van Dootnum GJ, Khoo SH, Hietholzer JC. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol 1999; 37:3940-5.
43. Blasiole DA, Metzgar D, Daum LT, Ryan MA, Wu J, Wills C, Le CT, Freed NE, Hansen CJ, Gray GC, Russell KL. Molecular analysis of adenovirus isolates from vaccinated and unvaccinated young adults. J Clin Microbiol 2004; 42:1686-93.
44. Berry GP, Kitchen SF. Yellow fever accidentally contracted in the laboratory. A study of seven cases. Am J Trop Med Trop 1931; 11:465-343.
45. Reed W, Carroll J, Agramonte A Experimental yellow fever. Trans Ass Am Phys 1901; xvi, 45-71.
46. In: Strode GK, Bugher JC, Austin-Kerr J, Smith HH, Smithburn KC, Taylor RM, Theiler M, Warren AJ, Whitman L, eds. Yellow Fever. New York: McGraw-Hill Book Company Inc., 1951:393,443.
47. Lepiniec L, Dalgarno L, Huong VT, Monath TP, Digoutte JP, Deubel V. Geographic distribution and evolution of yellow fever viruses based on direct sequencing of genomic cDNA fragments. J Gen Virol 1994; 75:417-23.
48. Breese Jr BB. Roseola infantum (exanthema subitum). NY State J Med 1941; 41:1854-9.
49. Hellstrom B, Vahlquist B. Experimental inoculation of roseola infantum. Acta Paediatr 1951; 40:189-197.
50. van Loon NM, Gummuluru S, Sherwood DJ, Marentes R, Hall CB, Dewhutst S. Direct sequence analysis of human herpesvirus 6 (HHV-6) sequences from infants and comparison of HHV-6 sequences from mother/infant pairs. Clin Infect Dis 1995; 21:1017-9.
51. Kusuhara K, Ueda K, Okada K, Miyazaki C, Tokugawa K, Hirose M, Takahashi K, Yamanishi K. Do second attacks of exanthema subitum result from human herpesvirus 6 reactivation or reinfection? Pediatr Infect Dis J 1991; 10:468-70.
52. Yoshida M, Torigoe S, Ikeue K, Yamada M. Neutralizing antibody responses to human herpesviruses 6 and 7 do not cross-react with each other, and maternal neutralizing antibodies contribute to sequential infection with these viruses in childhood. Clin Diagn Lab Immunol 2002; 9:388-93.
53. Horstmann DM, Paul JR. The incubation period in human poliomyelitis and its implication. JAMA 1947; 135:11-4.
54. Crainic R, Couillin P, Blondel B, Cabau N, Boue A, Hotodniceanu F. Natutal variation of poliovirus neutralization epitopes. Infect Immun 1983; 41:1217-25.
55. Lincoln AF, Sivertson SE. Acute phase of Japanese B encephalitis. Two hundred and one cases in American soldiers, Korea, 1950. JAMA 1952; 150:268-73.
56. Ni H, Batrett AD. Nucleotide and deduced amino acid sequence of the structural protein genes of Japanese encephalitis viruses from different geographical locations. J Gen Virol 1995; 76:401-7.
57. Solomon T, Ni H, Beasley DW, Ekkelenkamp M, Cardosa MJ, Barrett AD. Origin and evolution of Japanese encephalitis virus in Southeast Asia. J Virol 2003; 77:3091-8.
58. Chtistensen PE, Schmidt H, Bang HO, Andersen V, Jordal B, Jensen O. An epidemic of measles in southern Greenland Measles in vitgin soil. II. The epidemic proper. Acta Med Scand 1953; 144:408-29.
59. Hope-Simpson RE. Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps). Lancet 1952; 2:549-54.
60. Riddell MA, Rota JS, Rota PA. Review of the temporal and geographical distribution of measles virus genotypes in the prevaccine and postvaccine eras. Virol J 2005; 2:87-96.
61. Klingele M, Hartter HK, Adu F, Ammerlaan W, Ikusika W, Mullet CP. Resistance of recent measles virus wild-type isolares to antibody-mediated neutralization by vaccinees wirb antibody. J Med Virol 2000; 62:91-8.
62. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi I. Smallpox and its eradication. Chapter 4. Geneva: World Health Organization, 1988, (http://whqlibdoc.who.int/smallpox/9241561106_chp4.pdf).
63. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi I. Smallpox and its eradication. Chapter 2. Geneva: World Health Organization, 1988, (http://whqlibdoc.who.int/smallpox/9241561106_chp2.pdf).
64. Hatakeyama S, Moriya K, Saijo M, Motisawa Y, Kutane I, Koike K, Kimura S, Morikawa S. Persisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations. Clin Diagn Lab Immunol 2005; 12:520-4.
65. Gordon JE, Meadet FM. The period of infectivity and serum prevention of chickenpox. JAMA 1929; 93:2013-5.
66. Getshon AA, Steinbetg SP, Gelb L. Clinical reinfection with varicella-zostet virus. J Infect Dis 1984; 149:137-42.
67. Loparev VN, Gonzalez A, Deleon-Carnes M, Tipples G, Fickenscher H, Torfason EG, Schmid DS. Global identification of three major genotypes of varicella-zostet virus: Longitudinal clustering and strategies for genotyping. J Virol 2004; 78:8349-58.
68. Heggie AD, Robbins FC. Natural rubella acquired-after birth. Am J Dis Child 1969; 118:12-7.
69. Hattis RP, Halstead SB, Hermann KL, Witte JJ. Rubella in an immunized island population. JAMA 1973; 223:1019-21.
70. Standardization of the nomenclature for genetic characteristics of wild-type rubella viruses. Wkly Epidemiol Rec 2005; 80:126-32.
71. Horstmann DM, Liebhaber H, Le Bouvier GL, Rosenberg DA, Halstead SB. Rubella: Reinfection of vaccinated and naturally immune persons exposed in an epidemic. N Engl J Med 1970; 283:771-8.
72. Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, Pattison JR, Tyrrell DA. Experimental parvoviral infection in humans. J Infect Dis 1985; 152:257-65.
73. Joseph PR. Incubation period of fifth disease [Letter]. Lancet 1986; 2:1390-1.
74. Gallineila G, Venturoli S, Manaresi E, Musiani M, Zerbini M. B19 virus genome diversity: Epidemiological and clinical correlations. J Clin Virol 2003; 28:1-13.
75. Servant A, Laperche S, Lallemand F, Marinho V, De Saint Maur G, Meritet JF, Garbarg-Chenon A. Genetic diversity within human erythroviruses: Identification of three genotypes. J Virol 2002; 76:9124-34.
76. Meyer MB. An epidemioiogic study of mumps: Its spread in schools and families. Am J Hyg 1962; 75:259-81.
77. Gut JP, Lablanche C, Behr S, Kim A. Symptomatic mumps virus reinfections. J Med Virol 1995; 45:17-23.
78. Palacios G, Jabado O, Cisterna D, de Ory F, Renwick N, Echevarria JE, Castellanos A, Mosquera M, Freire MC, Campos RH, Lipkin WI. Molecular identification of mumps virus genotypes from clinical samples: Standardized method of analysis. J Clin Microbiol 2005; 43:1869-78.
79. Nojd J, Tecle T, Samuelsson A, Orvell C. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous Mumps virus genotype. Vaccine 2001; 19:1727-31.
80. Kaiser R. The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98: A prospective study of 656 patients. Brain 1999; 122:2067-78.
81. Kaiser R, Holzmann H. Laboratory findings in tick-borne encephalitis-correlation with clinical outcome. Infection 2000; 28:78-84.
82. Ecker M, Allison SL, Meixner T, Heinz FX. Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia. J Gen Virol 1999; 80:179-85.
83. Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993; 328:327-35.
84. Tindall B, Cooper DA. Primary HIV infection: Host responses and intervention strategies. AIDS 1991; 5:1-14.
85. Smith DM, Richman DD, Little SJ. HIV superinfection. J Infect Dis 2005; 192:438-44.
86. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, Gao F, Hahn BH, Kalish ML, Kuiken C, Learn GH, Leitner T, McCutchan F, Osmanov S, Peeters M, Pieniazek D, Salminen M, Sharp PM, Wolinsky S, Korber B. HIV-1 nomenclature proposal. Science 2000; 288:55-6, (http://hiv-web.lanl.gov/content/ hiv-db/HelpDocs/subtypes-mote.html).
87. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58:19-42.
88. Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci USA 2005; 102:14943-8.
89. Hooper RR, Juels CW, Routenberg JA, Harrison WO, Kilpatrick ME, Rendra SJ, Dienstag JL. An outbreak of type A viral hepatitis at the Naval Training Center, San Diego: Epidemiologic evaluation. Am J Epidemiol 1977; 105:148-55.
90. Hooper RR, Juels CW, Routenberg JA, et al. An outbreak of type A viral hepatitis at the Naval Training Center, San Diego: Epidemiologic evaluation. Am J Epidemiol 1977; 105:148-55.
91. Cohen JI, Ticehurst JR, Purcell RH, Buckler-White A, Baroudy BM. Complete nucleotide sequence of wild-rype hepatitis A virus: Comparison with different strains of hepatitis A virus and other picornaviruses. J Virol 1987; 61:50-9.
92. Brodsky AL, Heath CW. Infectious mononucleosis: Epidemiologic patterns at United States colleges and universities. Am J Epidemiol 1972; 96:87-93.
93. Hoagland RJ. The incubation period of infectious mononucleosis. Am J Public Health 1964; 54:1699-705.
94. Sitki-Green DL, Edwards RH, Covington MM, Raab-Ttaub N. Biology of Epstein-Barr virus during infectious mononucleosis. J Infect Dis 2004; 189:483-92.
95. Tierney RJ, Edwards RH, Sitki-Green D, Croom-Cartet D, Roy S, Yao QY, Raab-Traub N, Rickinson AB. Multiple EpsteinBarr virus strains in patients with infectious mononucleosis: Comparison of ex vivo samples with in vitro isolates by use of heteroduplex tracking assays. J Infect Dis 2006; 193:287-97.
96. Hemachudha T, Laothamatas J, Rupprecht C. Human tables: A disease of complex neuropathogenetic mechanisms and diagnostic challenges. Lancet Neurol 2002; 1:101-9.
97. Badrane H, Bahloul C, Perrin P, Tordo N. Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J Virol 2001; 75:3268-76.
98. Wiktor TJ, Gyorgy E, Schlumberger HD, Sokol F, Koprowski H. Antigenic properties of rabies virus components. J Immunol 1973; 110:269-76.
99. Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 1981; 98:281-7.
100. Stanton R, Westmoreland D, Fox JD, Davison AJ, Wilkinson GW. Stability of human cytomegalovirus genotypes in persistently infected renal transplant recipients. J Med Virol 2005; 75:42-6.
101. Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L, Addison C, Dargan DJ, McGeoch DJ, Gatherer D, Emery VC, Griffiths PD, Sinzger C, McSharry BP, Wilkinson GW, Davison AJ. Generic content of wild-type human cytomegalovirus. J Gen Virol 2004; 85:1301-12.
102. Esteban JI, Gomez J, Martell M, Cabot B, Quer J, Camps J, Gonzalez A, Otero T, Moya A, Esteban R, et al. Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996; 334:555-60.
103. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE, et al. The natural hisrory of community-acquired hepatitis C in the United States. The sentinel counties chronic non-A, non-B Hepatitis study team. N Engl J Med 1992; 327:1899-905.
104. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, Strathdee SA, Vlahov D, Thomas DL. Protection against persistence of hepatitis C. Lancet 2002; 359:1478-1483.
105. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194:1395-406.
106. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42:962-73.
107. Yu MY, Bartosch B, Zhang R, Guo ZR, Renzi PM, Shen LM, Granier C, Feinstone SM, Cosset FL, Purcell RH. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci USA 2004; 101:7705-10.
108. Parr L. Host variation in the manifestation of disease: With particular reference to homologous serum jaundice in the Army of the United States. Med Ann Distr of Columbia 1945; 14:443-49.
109. Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J Gen Virol 2002; 83:1267-80.
110. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost prorective antibodies after hepatitis B vaccination. Vaccine 2006; 24:572-7.
111. Rowson KE, Mahy BW. Human papova (wart) virus. Bacteriol Rev 1967; 31:110-31.
112. Ylitalo N, Josefsson A, Melbye M, Sorensen P, Frisch M, Andersen PK, Sparen R, Gustafsson M, Magnusson P, Ponten J, Gyllensten U, Adami HO. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000; 60:6027-32.
113. Mayrand MH, Coutlee F, Hankins C, Lapointe N, Forest R, de Ladurantaye M, Roger M. Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analysis. J Clin Microbiol 2000; 38:3388-93.
114. Carter JJ, Koutsky LA, Hughes JR Lee SK, Kuypers J, Kiviat N, Galloway DA. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181:1911-19.
115. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324:17-27.
116. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181:1911-19.
117. Richardson M, Elliman, D, Maguire H, Simpson J, Nicoll A. Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. Pediatric Inf Dis J 2001; 20:380-91.
118. Lipton P. Testing hypotheses: Prediction and prejudice. Science 2005; 307:219-21.